RAAS Flashcards
RAAS
Angiotensin II and aldosterone regulate fluid and BP
Renin
Produced in the kidney, release can be triggered by multiple factors:
Decrease in BP
Decrease in blood volume
Decrease in plasma sodium content
Decrease in renal perfusion
Renin causes formation of angiotensin I from angiotensin (secreted by liver)
Angiotensin system
Angiotensin I (inactive) has weak activity in the body, and precursor to II Kinase II (found in blood) converts angiotensin I to II
Angiotensin II
Vasoconstriction (more effect on arteries)
Stops nitric oxide to stop vasodilation
Stimulation of aldosterone
Angiotensin II indirect actions
Sympathetic neurons to promote NE release
Adrenal medulla to promote Epi release
On adrenal cortex to promote secretion of aldosterone
Aldosterone
Aldosterone acts on distal tubules in the kidney to cause sodium retention, and excretion of K+ and H+
4 main drug families affect RAAS
ACE inhibitors
ARBs (angiotensin II receptor blockers)
Direct renin inhibitors (DRIs)
Aldosterone antagonists
ACE inhibitors
Stop conversion of angiotensin I to II
Adverse effects include cough, angioedema, first dose hypotension, and hyperkalemia
More ACE inhibitors sides
10% get dry, persistent cough
Stopping can cause potassium retention in kidney
HyperK+ rare, but pts shouldn’t be taking K+ supp
ACE inhibitor MAO
Reduce level of angiotensin II
Increase levels of bradykinin (inhibits kinase II)
End result is non constricted blood vessels and stop release of aldosterone
Ace inhibitor name
Pril Benazepril Captopril Enalapril Lisinopril Ramipril
ARBs
Block actions of angiotensin II
Lower risk of cough and hyperk+
Usually secondary to ace inhibitors which have better success in decreased cardiac morbidity and mortality
ARBs
Block angiotensin II, also block release of aldosterone and so Na+ and H2O excretion is increased
ARBs names
Sartan Losartan Valsartan Olmesartan Eprosartan Candesartan
DRIs
Direct Renin inhibitors
Act on renin to inhibit conversion of angiotensin to angiotensin I
Aliskiren is the only one, used for HTN
Aldosterone antagonists
Block receptors for aldosterone for HTN and heart failure
2 drugs - eplerenone and spironolactone - K+ sparing diuretic
Aldosterone receptors
In the kidney, activation of aldosterone receptors promotes excretion of K and retention of Na+ and H2O
Receptor blockade has opposite effect, retention of K+ and excretion of Na+ and H2O
ACE inhibitors used in
HTN, CHF, diabetic neuropathy, MI and prevention of cardiovascular risks
ARBS indications
HTN, CHF, diabetic neuropathy
Aldosterone agonist indications
HTN, CHF also hypokalemia and hyperaldosteronism
DRIs
Direct renin inhibitors, for HTN
Angiotensions
I II and III
I is a precursor to II and isn’t very active
II is very active
III is from degradation of II and is moderately active
Angiotensin II vasoconstriction
Direct vascular smooth muscle activation (more arterial than veins because of this) and also causes release of norepi, promotes medulla to release epi and CNS to increase sympa outflow to vessels
Aldosterone
Released from angio II below vasoconstriction threshold.
From low Na+ or high K_
Acts on DISTAL tubules to retain sodium and excrete K+ and H+
Angio II formed through
Renin, ACE
Renin
Catalyzes angio I from angiotensin
It is the rate limiting step in I and II formation (II needs I)
Produced by juxtaglomerular cells of kindey
Renin is released from
Drop in BP, volume, Na+ or renal perfusion
ACE (kinase II)
Converts I to II
On luminal surface of all blood vessels, lungs are especially rich
Called Kinase II when acting on bradykinin
Angio II promoting renal water retention
Takes days weeks or even months
Constricts renal vessels to reduce GFR and stimulates release of aldosterone
ACE inhibitors adverse effects
Cough, angioedema, first dose hypotension and hyperkalemia
Kinase II (ACE) effects
If ACE is blocked, angio II goes down but bradykinin goes up (can’t be converted to inactive)
Vasodilation (secondary to increase prostaglandins and nitric oxide), cough and rarely angio edema occur
Effects of decreasing ACE (ace inhibitors)
Vasodilation, decreased volume and cardiac remodeling, potassium retention, fetal injury
ACE inhibitors suffix
PRIL
ACE inhibitors renal failure
Renally excreted, therefore need reduced dose for renal failure pts
Non BP effects on angio II
Increased migration, proliferation and hypertrophy of vasc smooth muscle cells
Increased ECM in VSM cells
Hypertrophy of cardiac myocytes
Increased ECG matrix by cardiac fibroblasts
(this means it contributes to atherosclerosis and blocking lowers risk of MI and stroke)
ACE inhibitors in heart failure
Lower arterial tone to improve blood flow
Reduce afterload to increase CO
Venos dilation improves pulmonary congestion and edema
Dilate kidney vessels to improve flow
Excrete Na+ and volume which reduces edema and preload (drops right sided strain)
ACE inhibitors for post MI pts
Captopril, lisinopril, trandolapril
ACE inhibitors kidneys
Reduce glomerular filtration pressure to prevent damage.
When renal efferent arterial pressure is increased it increases back pressure in glomerulus
Slows progression of established nephropathy but does not protect against kidney damage
Coversyl
Ace inhibitor, perindopril
ACE in renal failures
If renal stenosis is present, angio II is good as it maintains renal perfusion
ACE inhibitors interactions
Can cause lithium to accumulate
NSAIDS reduce antihypertensive effects
Indapamide
Thiazide like diuretic. Incombo with coversyl called coversyl plus
Rampiril
On its on. Altace is combine with HCT (hydrochlorothiazide)
ARBS vs ACE inhibs
Biggest difference is no hyperK+ or cough with ARBS
ARBS aren’t proven to lower odds of MI/STROKE as well as ACE inhibitors
ARBS suffix
Sartans
ARBS are reserved for pts who can’t tolerate ACE inhibs as mortality benefits aren’t proven with ARBS
Angioedema
More common in ACE inhibitors but both may cause it and is an absolute contraindication
MOA aliskiren a DRI
Binds to renin tightly and inhibits its ability to clean angio into angio I and therefore reduces both angio II and aldosterone
Only approved for HTN
Aldosterone antagonists are
Spironolactone and eplerenone. Spironolactone is less selective
MOA Aldosterone antagonists
Blocks aldosterone (selectively so no effect on glucocorticoids, progresterone, androgens) blocking aldosterone and so increases K+ and decreases Na+ Metabolized by CYP3A4 and inhibtors of 3A4 have a very strong effect on drug concentration